Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:56:22.559Z.
Consensus retrieved: 2026-10-06T10:18:25.131Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:56:22.559Z.
Quote observation: 2026-10-06T14:55:27.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6abed0f02887b3ac62520bc322e243c8ff06f4fcddd7c97914d2a236e2670171
Forward PE Ratio (N/A) = Dated Quote Price ($11.05) / Consensus Forward EPS ($-1.30)
FORWARD PE RATIO
N/A
ClearPoint Neuro, Inc.
Market Cap
$331.54M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| ClearPoint Neuro, Inc. (CLPT) | $331.54M | N/A |
| Agenus Inc. (AGEN)vs › | $332.31M | 29.83 |
| CapsoVision, Inc. (CV)vs › | $322.98M | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $320.81M | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $320.09M | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $345.16M | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $350.32M | N/A |
| Opus Genetics, Inc. (IRD)vs › | $350.35M | N/A |
| Embecta Corp. (EMBC)vs › | $353.89M | 3.38 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $354.67M | 36.04 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $11.05, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.30 | $-1.32 – $-1.29 | 1 | n/m |
| 2027-12-31 | $-1.20 | $-1.21 – $-1.18 | 1 | n/m |
| 2028-12-31 | $-0.98 | $-0.99 – $-0.97 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
